メールサービス キャンペーン : 期間中に新規登録や配信希望カテゴリの変更等をされた方に、ご用意した無料レポートを提供しております。 新規登録 / 登録内容変更

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

乾癬治療薬市場分析:治療クラス別(腫瘍壊死因子阻害剤、インターロイキン阻害剤、ビタミンDアナローグ)、治療別(局所、全身、生物製剤)、および動向分析

Psoriasis Drugs Market Analysis by Therapeutic Class (Tumor Necrosis Factor-inhibitors, Interleukin-inhibitors, Vitamin D analogues), by Treatment (Topicals, Systemic, Biologics) And Segment Forecasts, 2016 - 2022

発行 Grand View Research, Inc. 商品コード 582019
出版日 ページ情報 英文 171 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.61円で換算しております。
Back to Top
乾癬治療薬市場分析:治療クラス別(腫瘍壊死因子阻害剤、インターロイキン阻害剤、ビタミンDアナローグ)、治療別(局所、全身、生物製剤)、および動向分析 Psoriasis Drugs Market Analysis by Therapeutic Class (Tumor Necrosis Factor-inhibitors, Interleukin-inhibitors, Vitamin D analogues), by Treatment (Topicals, Systemic, Biologics) And Segment Forecasts, 2016 - 2022
出版日: 2017年11月03日 ページ情報: 英文 171 Pages
概要

当レポートでは、世界の乾癬治療薬市場について調査し、市場の概要と治療クラス別、治療別、および地域別の動向、市場に参入する企業のプロファイルなどをまとめています。

第1章 調査方法と調査範囲

第2章 エグゼクティブサマリー

第3章 疾患概要と疫学

  • 疾患概要
    • 種類
    • 病態生理学
    • 合併症
  • 適応別疫学
  • 主要7か国の現在の罹患率と件数
  • 主要7か国の現在の発症率と件数
  • 主要7か国の罹患率、発症率予測

第4章 世界市場概要

  • イントロダクションと市場概要
    • 治療クラス別市場
    • 治療別市場
    • 市場規模と予測
    • 販売実績
    • 市場シェアの分布
    • 主要製品概要
  • 特許失効分析
  • 促進因子と課題
  • M&A取引動向
  • 価格と償還環境
  • バイオシミラーの発展
  • 新興市場
  • SWOT分析

第5章 製品パイプライン

  • パイプライン環境
  • 有望候補薬

第6章 競合環境

第7章 市場見通し

目次
Product Code: GVR-1-68038-662-2

The global psoriasis therapeutics market is expected to be valued at USD 21.4 billion by 2022, according to a new report by Grand View Research, Inc. The increasing number of reimbursement policies for treatment, advanced diagnostic tools, rising disease awareness and improved technological systems are likely to increase the adoption of therapeutics.

Additionally, the rising prevalence and incidence of psoriasis is anticipated to fuel the market growth. The condition has neither exact causes nor treatments to cure. Certain environmental and genetic factors may trigger the disease onset. Most treatments for the condition target to decelerate the severity of the disease by stopping the keratinocyte hyperproliferation. The disease symptoms can be managed by following a healthy lifestyle.

Psoriasis can be classified into five types: Plaque, Guttate, Inverse, Pustular and Erythrodermic. The types vary in characterization of lesions and location of the body affected. Plaque psoriasis is the commonest and erythrodermic psoriasis is the rarest type of psoriasis affecting patients all over the world.

The prevalence of psoriasis has seen a gradual increase over the years across the different geographical locations. This increase in prevalence can be related to lifestyle changes, environmental and genetic factors triggering the condition and its implications. This could also be related to the resistance or declining response to therapies for controlling the disease

Further key findings from the report suggest:

Tumor Necrosis Factor-inhibitors dominated the market in 2016 owing to its higher usage by healthcare practitioners and easy availability.

TNF-inhibitors are likely to lose market shares over the forecast period due to increasing adoption of IL-inhibitor therapy over conventional TNF-inhibitors

Interleukin-inhibitors is expected to grow at a lucrative CAGR of over 19.0% over the forecast period because of improved safety and efficacy profiles of Interleukin-inhibiting drugs.

The U.S is the dominant regional market.in the psoriasis space in terms of revenue in 2016 due to the increasing number of patients seeking treatment and presence of well-established healthcare services.

Japan is expected to be the fastest growing region over the next decade with a lucrative CAGR from 2016 to 2022 due to growing awareness about the disease among the people.

Some of the key players in this industry are AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Eli Lilly & Company, AstraZeneca and Celgene Corporation.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information procurement
  • 1.2 Information or Data Analysis
    • 1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary

  • 2.1 Disease Primer and Epidemiology
  • 2.2 Global Market Overview
  • 2.3 Product Pipeline
  • 2.4 Competitive Landscape
  • 2.5 Market Outlook
  • 2.6 Market Snapshot, 2016

Chapter 3 Disease Primer and Epidemiology

  • 3.1 Disease Primer
    • 3.1.1 Types:
      • 3.1.1.1 Plaque Psoriasis
      • 3.1.1.2 Guttate Psoriasis
      • 3.1.1.3 Inverse Psoriasis
      • 3.1.1.4 Pustular Psoriasis
      • 3.1.1.5 Erythrodermic Psoriasis
    • 3.1.2 Pathophysiology
    • 3.1.3 Complications
  • 3.2 Epidemiology by indications
  • 3.3 Current prevalence rate and numbers for 7 major markets (U.S., Japan, EU5)
  • 3.4 Current incidence rate and numbers for 7 major markets (U.S., Japan, EU5)
  • 3.5 Forecast prevalence and incidence for 7 major markets (U.S., Japan, EU5)

Chapter 4 Global Market Overview

  • 4.1 Introduction and Market Overview
    • 4.1.1 Market by Therapeutic Class
      • 4.1.1.1 Tumour Necrosis Factor Inhibitors
      • 4.1.1.1.1 Adalimumab
      • 4.1.1.1.2 Infliximab
      • 4.1.1.1.3 Etanercept
      • 4.1.1.2 Interleukin-Inhibitors
      • 4.1.1.2.1 Ustekinumab
      • 4.1.1.2.2 Secukinumab
      • 4.1.1.2.3 Ixekizumab
      • 4.1.1.2.4 Brodalumab
      • 4.1.1.3 Vitamin D analogues
      • 4.1.1.3.1 Calcitriol
      • 4.1.1.3.2 Calcipotriol
      • 4.1.1.3.3 Tacalcitol
      • 4.1.1.4 Others
    • 4.1.2 Market by Treatment
      • 4.1.2.1 Topicals
      • 4.1.2.1.1 Over-the-counter (OTC) Topicals
      • 4.1.2.1.2 Topical non-steroids
      • 4.1.2.1.3 Topical Steroids
      • 4.1.2.2 Systemic
      • 4.1.2.2.1 Retinoid
      • 4.1.2.2.2 Cyclosporine
      • 4.1.2.2.3 Methotrexate
      • 4.1.2.3 Biologics
      • 4.1.2.3.1 Tumour necrosis factor alpha (TNF-α) inhibitors
      • 4.1.2.3.2 Interleukin 12 and 23 (IL-12/23) inhibitors
      • 4.1.2.3.3 Interleukin 17 (IL-17) inhibitor
      • 4.1.2.3.4 T cell inhibitor
    • 4.1.3 Market size & Forecast
    • 4.1.4 Sales Performance
    • 4.1.5 Market Share Distribution, 2016
    • 4.1.6 Major Product Overview
      • 4.1.6.1 Humira
      • 4.1.6.2 Remicade
      • 4.1.6.3 Enbrel
      • 4.1.6.4 Stelara
      • 4.1.6.5 Cosentyx
      • 4.1.6.6 Taltz
      • 4.1.6.7 Otezla
    • 4.1.7 Market Dynamics among Leading Brands
  • 4.2 Patent Expiry Analysis
  • 4.3 Drivers and Challenges
  • 4.4 M&A, Deal Landscape (2013-2017 YTD)
  • 4.5 Pricing and Reimbursement Environment
  • 4.6 Biosimilar Evolution (India, China, South Korea)
    • 4.6.1 India
    • 4.6.2 China
    • 4.6.3 South Korea
  • 4.7 Emerging Markets
  • 4.8 SWOT Analysis

Chapter 5 Product Pipeline

  • 5.1 Pipeline Landscape
    • 5.1.1 Leading drugs in development
      • 5.1.1.1 Mode of Approach: Injectables
      • 5.1.1.2 Mode of Approach: Oral
      • 5.1.1.3 Mode of Approach: Topical
      • 5.1.1.4 Mode of Approach: Biosimilar
    • 5.1.2 Key R&D Trends
  • 5.2 Promising Drug Candidates in Pipeline
    • 5.2.1 Late Stage Pipeline and Sales Forecast
    • 5.2.2 Profile of disruptive drugs
      • 5.2.2.1 GP2015 (Erelzi)
      • 5.2.2.2 GP2017
      • 5.2.2.3 ABP501 (Amjevita)
      • 5.2.2.4 BI 655066
      • 5.2.2.5 Cimzia
      • 5.2.2.6 Tildrakizumab
      • 5.2.2.7 BI695501

Chapter 6 Competitive Landscape

  • 6.1 AbbVie Inc.
    • 6.1.1 Company overview
    • 6.1.2 Current Product Portfolio
    • 6.1.3 Product Forecast Sales up to 2022
    • 6.1.4 Strategic initiatives(Humira)
    • 6.1.5 Company - Key News Flow
    • 6.1.6 Pipeline View
    • 6.1.7 Pipeline Forecast
    • 6.1.8 Catalysts and Event Calendar
    • 6.1.9 SWOT Analysis
  • 6.2 Amgen, Inc.
    • 6.2.1 Company overview
    • 6.2.2 Current Product Portfolio
    • 6.2.3 Product Forecast Sales up to 2022
    • 6.2.4 Strategic initiatives(Enbrel)
    • 6.2.5 Company - Key News Flow
    • 6.2.6 Pipeline View
    • 6.2.7 Pipeline Forecast
    • 6.2.8 Catalysts and Event Calendar
    • 6.2.9 SWOT Analysis
  • 6.3 Johnson & Johnson
    • 6.3.1 Company overview
    • 6.3.2 Current Product Portfolio
    • 6.3.3 Product Forecast Sales up to 2022
    • 6.3.4 Strategic initiatives
      • 6.3.4.1 Remicade
      • 6.3.4.2 Stelara
      • 6.3.4.3 Tremfya
    • 6.3.5 Company - Key News Flow
    • 6.3.6 Pipeline View
    • 6.3.7 Pipeline Forecast
    • 6.3.8 Catalysts and Event Calendar
    • 6.3.9 SWOT Analysis
  • 6.4 Novartis AG
    • 6.4.1 Company overview
    • 6.4.2 Current Product Portfolio
    • 6.4.3 Product Forecast Sales up to 2022
    • 6.4.4 Strategic initiatives(Cosentyx)
    • 6.4.5 Company - Key News Flow
    • 6.4.6 Pipeline View
    • 6.4.7 Pipeline Forecast
    • 6.4.8 Catalysts and Event Calendar
    • 6.4.9 SWOT Analysis
  • 6.5 Eli Lilly and Company
    • 6.5.1 Company overview
    • 6.5.2 Current Product Portfolio
    • 6.5.3 Product Forecast Sales up to 2022
    • 6.5.4 Strategic initiatives(Taltz)
    • 6.5.5 Company - Key News Flow
    • 6.5.6 Pipeline View
    • 6.5.7 Pipeline Forecast
    • 6.5.8 Catalysts and Event Calendar
    • 6.5.9 SWOT Analysis
  • 6.6 AstraZeneca
    • 6.6.1 Company overview
    • 6.6.2 Current Product Portfolio
    • 6.6.3 Strategic initiatives(Siliq)
    • 6.6.4 Company - Key News Flow
    • 6.6.5 Pipeline View
    • 6.6.6 Pipeline Forecast
    • 6.6.7 Catalysts and Event Calendar
    • 6.6.8 SWOT Analysis
  • 6.7 Celgene Corporation
    • 6.7.1 Company overview
    • 6.7.2 Current Product Portfolio
    • 6.7.3 Product Forecast Sales up to 2022
    • 6.7.4 Strategic initiatives(Otezla)
    • 6.7.5 Company - Key News Flow
    • 6.7.6 Pipeline View
    • 6.7.7 Pipeline Forecast
    • 6.7.8 Catalysts and Event Calendar
    • 6.7.9 SWOT Analysis

Chapter 7 Market Outlook

  • 7.1 What the future holds
  • 7.2 Winners and Losers
  • 7.3 Emerging Companies
  • 7.4 The road ahead

List of Tables

  • TABLE 1 Current prevalence rates and numbers across 7 major markets - 2016
  • TABLE 2 Current incidence rates and numbers across 7 major markets - 2016
  • TABLE 3 Forecast global prevalence 2016 - 2022
  • TABLE 4 Forecast global incidence 2016 - 2022
  • TABLE 5 Forecast prevalence for 7 major markets 2016 - 2022
  • TABLE 6 Forecast incidence for 7 major markets 2016 - 2022
  • TABLE 7 Psoriasis therapeutics market size and forecast
  • TABLE 8 Geographic sales performance of psoriasis therapeutics by region
  • TABLE 9 Psoriasis therapeutic market by drug class
  • TABLE 10 Forecast sales of leading brands in the global psoriasis market
  • TABLE 11 Global psoriasis pipeline forecast
  • TABLE 12 Global psoriasis pipeline sales forecast
  • TABLE 13 Psoriasis sales forecast by company
  • TABLE 14 Psoriasis therapeutic market share by company
  • TABLE 15 Patent Expiry Analysis
  • TABLE 16 M&A, Deal Landscape
  • TABLE 17 Mode of Approach: Injectables
  • TABLE 18 Mode of Approach: Oral
  • TABLE 19 Mode of Approach: Topical
  • TABLE 20 Mode of Approach: Biosimilar
  • TABLE 21 Late-stage pipeline and sales forecast
  • TABLE 22 Product Profile: GP2015 (Erelzi)
  • TABLE 23 Product Profile: GP2017
  • TABLE 24 Product Profile: ABP501 (Amjevita)
  • TABLE 25 Product Profile: BI655066
  • TABLE 26 Product Profile: Cimzia
  • TABLE 27 Product Profile: Tildrakizumab
  • TABLE 28 Product Profile: BI695501
  • TABLE 29 Product Portfolio: Humira
  • TABLE 30 Humira forecast sales up to 2022
  • TABLE 31 AbbVie pipeline view
  • TABLE 32 AbbVie catalysts and event calendar
  • TABLE 33 Product Portfolio: Enbrel
  • TABLE 34 Enbrel forecast sales up to 2022
  • TABLE 35 Amgen pipeline view
  • TABLE 36 Amgen catalysts and event calendar
  • TABLE 37 Product Portfolio: Remicade
  • TABLE 38 Product Portfolio: Stelara
  • TABLE 39 Product Portfolio: Tremfya
  • TABLE 40 Remicade product forecast sales upto 2022
  • TABLE 41 Stelara product forecast sales upto 2022
  • TABLE 42 Tremfya product forecast sales upto 2022
  • TABLE 43 Johnson & Johnson pipeline view
  • TABLE 44 Johnson & Johnson catalysts and event calendar
  • TABLE 45 Product Portfolio: Cosentyx
  • TABLE 46 Cosentyx product forecast sales upto 2022
  • TABLE 47 Novartis pipeline view
  • TABLE 48 Novartis catalysts and event calendar
  • TABLE 49 Product Portfolio: Taltz
  • TABLE 50 Taltz forecast sales up to 2022
  • TABLE 51 Eli Lilly pipeline view
  • TABLE 52 Eli Lilly catalysts and event calendar
  • TABLE 53 Product Portfolio: Siliq
  • TABLE 54 AstraZeneca pipeline view
  • TABLE 55 AstraZeneca catalysts and event calendar
  • TABLE 56 Product Portfolio: Otezla
  • TABLE 57 Otezla forecast sales up to 2022
  • TABLE 58 Celgene pipeline view
  • TABLE 59 Celgene catalysts and event calenadar

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary, 2016
  • FIG. 8 Current prevalence rates and numbers across 7 major markets - 2016
  • FIG. 9 Current incidence rates and numbers across 7 major markets - 2016
  • FIG. 10 Global psoriasis epidemiology 2016 - 2022
  • FIG. 11 Market segmentation & scope
  • FIG. 12 Psoriasis therapeutic market by drug class
  • FIG. 13 Psoriasis market share by company 2016 - 2022
  • FIG. 14 Market trends & outlook
  • FIG. 15 Market driver relevance analysis (Current & future impact)
  • FIG. 16 Market restraint relevance analysis (Current & future impact)
  • FIG. 17 SWOT Analysis (Psoriasis therapeutic sector)
  • FIG. 18 SWOT Analysis (AbbVie)
  • FIG. 19 SWOT Analysis (Amgen)
  • FIG. 20 SWOT Analysis (Johnson & Johnson)
  • FIG. 21 SWOT Analysis (Novartis)
  • FIG. 22 SWOT Analysis (Eli Lilly)
  • FIG. 23 SWOT Analysis (AstraZeneca)
  • FIG. 24 SWOT Analysis (Celgene)
Back to Top